Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of the phase III LUME-colon 1 study.
Van Cutsem, E Yoshino, T Lenz, H Lonardi, S Falcone, A Limon, M Saunders, Mark P Sobrero, A. Maiello, E. Park, Y.S.
Van Cutsem, E
Yoshino, T
Lenz, H
Lonardi, S
Falcone, A
Limon, M
Saunders, Mark P
Sobrero, A.
Maiello, E.
Park, Y.S.
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of the phase III LUME-colon 1 study. 2016, 27(suppl_6):LBA20_PR Annals of Oncology